HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating for Cullinan Therapeutics (NASDAQ:CGEM) and maintained a price target of $28.
October 16, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating for Cullinan Therapeutics and maintained a price target of $28, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $28 price target by a reputable analyst suggests positive sentiment and confidence in Cullinan Therapeutics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100